SEC Company Response from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Jul 26, 2016
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: July 26, 2016 · CIK: 0001671502 · Accession: 0001144204-16-114562
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212432
Letter
Cellect Biotechnology Ltd.
23 Hata’as Street
Kfar Saba, Israel 44425
July 26, 2016
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE: Cellect Biotechnology Ltd. (CIK: 0001671502)
Registration Statement No. 333-212432 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Cellect Biotechnology Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on July 28, 2016 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant acknowledges that:
· should the Securities and Exchange Commission (the “Commission”) or its staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
· the action of the Commission or its staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
Very truly yours,
CELLECT BIOTECHNOLOGY LTD.
Show Raw Text
CORRESP
1
filename1.htm
Cellect Biotechnology Ltd.
23 Hata’as Street
Kfar Saba, Israel 44425
July 26, 2016
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Cellect Biotechnology Ltd. (CIK: 0001671502)
Registration Statement No. 333-212432 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Cellect Biotechnology
Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that
it may become effective on July 28, 2016 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant acknowledges
that:
·
should the Securities and Exchange Commission (the “Commission”) or its staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
·
the action of the Commission or its staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
·
the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Registrant
understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement
as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the
proposed public offering of the securities specified in the Registration Statement.
Very truly yours,
CELLECT BIOTECHNOLOGY LTD.
By: /s/ Dr. Shai Yarkoni
Dr. Shai Yarkoni, Chief Executive Officer